指南与共识老年慢病共病管理衰弱、肌少症与跌倒多重用药

75岁以上无动脉粥样硬化性心血管病史成人高胆固醇血症管理:美国国家脂质协会与美国老年医学会专家临床共识

Managing Hypercholesterolemia in Adults Older Than 75 years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus From the National Lipid Association and the American Geriatrics Society.
指南 / 共识 · J Am Geriatr Soc · 2025-04-10

该专家临床共识针对75岁以上无动脉粥样硬化性心血管病(ASCVD)史的成人,讨论高胆固醇血症的管理。共识指出该人群LDL-C和非HDL-C仍可预测ASCVD事件,但现有风险计算器在该人群特异性不足且未调整共病、功能状态、衰弱和认知。他汀一级预防可能减少ASCVD事件且获益大于风险,需共同决策,特定终末期患者可考虑减停降脂药。

要点

  • 75岁以上无ASCVD史者,LDL-C和非HDL-C仍预测ASCVD事件。
  • 现有风险计算器在75岁以上人群特异性不足,未调整共病、功能、衰弱和认知。
  • 他汀一级预防可能减少ASCVD事件,获益大于肌痛和新发2型糖尿病等风险。

核心结论

  • 对于75岁以上无ASCVD史的成人,他汀一级预防可能减少ASCVD事件,获益大于潜在风险。
  • 考虑他汀治疗时应进行共同决策,并采取以患者为中心的一级预防策略。
  • 对患有终末期疾病的特定75岁以上患者,减停降脂药物可能是合适的。

研究设计与样本

  • 美国国家脂质协会与美国老年医学会发布的专家临床共识。

主要发现

  • LDL-C和非HDL-C水平在75岁以上人群中仍预测新发ASCVD事件。
  • 现有风险计算器在75岁以上人群缺乏特异性,且未调整共病、功能状态、衰弱和认知。
  • 他汀一级预防试验多纳入较年轻患者,75岁以上无ASCVD史人群的获益与风险数据有限。
  • 现有数据提示他汀治疗可能减少老年一级预防患者的ASCVD事件。
  • 多数文献提示他汀对认知影响为中性甚至保护性,尽管有证据提示可能相关认知损害。

关键数值与推荐

  • 推荐所有患者在考虑他汀治疗时进行共同决策,老年患者尤其重要。
  • 对患有终末期疾病的特定75岁以上患者,减停降脂药物可能是合适的。
  • 非他汀降脂治疗在老年患者中的随机临床试验数据稀少。

临床怎么用

  • 对75岁以上无ASCVD史患者评估血脂时,应结合共病、功能状态、衰弱和认知进行个体化风险判断。
  • 启动他汀前应与患者共同决策,权衡ASCVD事件减少与肌痛、新发2型糖尿病等风险。
  • 对患有终末期疾病的特定75岁以上患者,可考虑减停降脂药物。

局限性

  • 多数一级预防试验主要纳入较年轻患者,75岁以上无ASCVD史人群数据有限。
  • 现有风险计算器在75岁以上人群缺乏特异性,且未调整共病、功能状态、衰弱和认知。
  • 非他汀降脂治疗在老年患者中的随机临床试验数据稀少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The risk of atherosclerotic cardiovascular disease increases with advancing age. Elevated LDL-cholesterol and non-HDL-cholesterol levels remain predictive of incident atherosclerotic cardiovascular events among individuals older than 75 years. Risk prediction among older individuals is less certain because most current risk calculators lack specificity in those older than 75 years and do not adjust for co-morbidities, functional status, frailty, and cognition which significantly impact prognosis in this age group. Data on the benefits and risks of lowering LDL-cholesterol with statins in older patients without atherosclerotic cardiovascular disease are also limited since most primary prevention trials have included mostly younger patients. Available data suggest that statin therapy in older primary prevention patients may reduce atherosclerotic cardiovascular events and that benefits from lipid-lowering with statins outweigh potential risks such as statin-associated muscle symptoms and incident Type 2 diabetes mellitus. While some evidence suggests the possibility that statins may be associated with incident cognitive impairment in older adults, a preponderance of literature indicates neutral or even protective statin-related cognitive effects. Shared decision-making which is recommended for all patients when considering statin therapy is particularly important in older patients. Randomized clinical trial data evaluating the use of non-statin lipid-lowering therapy in older patients are sparse. Deprescribing of lipid-lowering agents may be appropriate for select patients older than 75 years with life-limiting diseases. Finally, a patient-centered approach should be taken when considering primary prevention strategies for older adults.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Bittner V, Linnebur SA, Dixon DL, et al. Managing Hypercholesterolemia in Adults Older Than 75 years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus From the National Lipid Association and the American Geriatrics Society. J Am Geriatr Soc. 2025. PMID: 40207842. doi:10.1111/jgs.19398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。